Moreover, analyses of NPK metastatic allografts in vivo revealed that Nsd2 silencing resulted in increased overall survival (n = 10/group; p = 0.0005, log-rank; Fig. 6a) as well as a significant reduction of metastatic burden while not affecting primary tumor growth (n = 9/group; p < 0.03, Mann–Whitney U test; Fig. 6b–d). This evidence concerns the gene NSD2 and neoplasm.